Document is current

Article History

Received: 18 November 2022

Accepted: 11 April 2023

First Online: 15 April 2023

Declarations

:

: All subjects signed an informed consent. The study was approved by the ethics committees and/or institutional review boards of The University of California San Diego, The Washington Center for Bleeding Disorders and The Orthopaedic Institute for Children. All experiments were performed in accordance with relevant guidelines and regulations.

: The written informed consent also included patient permission to utilize and publish ultrasound images and other body images with a potential for patient identification.

: A.v.D. has received honoraria for participating on scientific advisory boards, consulting, and speaking engagements for Sanofi/Bioverativ, Spark, Takeda, CSL-Behring, Biomarin and Uniqure, and has received research funding from Bioverativ/Sanofi and Pfizer. A.v.D. is a co-founder and member of the Board of Directors of Hematherix Inc., a company that is developing superFVa therapy for bleeding complications. She is the inventor for the Joint Activity and Damage Examination (JADE) Ultrasound measurement tool. The JADE measurement tool is copyrighted and is commercialized by the University of California San Diego. D.V.Q. has received honoraria for participating on scientific advisory boards, consulting, or advisory committees, and speakers’ bureau for Novo Nordisk, Genentech/Roche, Biomarin, Uniqure, Bayer, Bioverativ/Sanofi, Hema Biologics and Shire/Takeda. R.K.J. has received honoraria for participating on scientific advisory boards and consulting for CSL Behring, Roche, Pfizer, Bayer, and Baxalta/Shire. BS has received honoraria for participating on scientific advisory boards, consulting, and speaking engagements for Bioverativ, Sanofi, Genentech, Roche and Uniqure, and has received research funding from Bioverativ/Sanofi, Genentech, Roche, Uniqure and Pfizer. The remaining authors have no other conflicts of interest or funding to disclose.